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Abstract
Background: Accuracy in the diagnosis of breast cancer and classification of cancer subtypes has improved over
the years with the development of well-established immunohistopathological criteria. More recently, diagnostic
gene-sets at the mRNA expression level have been tested as better predictors of disease state. However, breast
cancer is heterogeneous in nature; thus extraction of differentially expressed gene-sets that stably distinguish
normal tissue from various pathologies poses challenges. Meta-analysis of high-throughput expression data using
a collection of statistical methodologies leads to the identification of robust tumor gene expression signatures.
Methods: A resampling-based meta-analysis strategy, which involves the use of resampling and application of
distribution statistics in combination to assess the degree of significance in differential expression between sample
classes, was developed. Two independent microarray datasets that contain normal breast, invasive ductal
carcinoma (IDC), and invasive lobular carcinoma (ILC) samples were used for the meta-analysis. Expression of
the genes, selected from the gene list for classification of normal breast samples and breast tumors encompassing
both the ILC and IDC subtypes were tested on 10 independent primary IDC samples and matched non-tumor
controls by real-time qRT-PCR. Other existing breast cancer microarray datasets were used in support of the
resampling-based meta-analysis.
Results: The two independent microarray studies were found to be comparable, although differing in their
experimental methodologies (Pearson correlation coefficient, R = 0.9389 and R = 0.8465 for ductal and lobular
samples, respectively). The resampling-based meta-analysis has led to the identification of a highly stable set of
genes for classification of normal breast samples and breast tumors encompassing both the ILC and IDC subtypes.
The expression results of the selected genes obtained through real-time qRT-PCR supported the meta-analysis
results.
Conclusion: The proposed meta-analysis approach has the ability to detect a set of differentially expressed genes
with the least amount of within-group variability, thus providing highly stable gene lists for class prediction.
Increased statistical power and stringent filtering criteria used in the present study also make identification of
novel candidate genes possible and may provide further insight to improve our understanding of breast cancer
development.
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Microarray studies aiming to identify differentially
expressed as well as co-regulated gene sets and signaling
pathways involved in different cellular states have greatly
improved our understanding of breast cancer at the
molecular level. The power of expression profiling using
cDNA or DNA microarrays for distinguishing subgroups
of breast cancers has been demonstrated by several groups
[1-4].
The identification of an intrinsic gene-set exhibiting high
variability among different tumor clusters has been
informative in describing different subtypes of breast can-
cer samples. However, only a few papers have been pub-
lished on gene expression profiles of normal cell
populations in breast tissue [5-9]. Therefore, it is of para-
mount importance for the research community in the
field of tumor biology to have access to gene lists that
exhibit low variability in expression among tumors and
yet are distinguishable from a normal tissue profile.
Meta-analysis of microarray datasets has the potential to
lead to more comprehensive measures of the existing dif-
ferential gene expression data and can therefore provide
gene sets with a high diagnostic value. Meta-analysis of
independent microarray datasets generated with the com-
mon objective of identifying differentially expressed genes
in a certain type of cancer has also been performed for
breast cancer. In a very recent meta-analysis study, Smith
et al. identified differentially expressed genes between ER+
and ER- breast tumors by gathering 9 independent breast
cancer microarray studies [10]. Another study used the
power of meta-analysis to find out the relation of expres-
sion patterns of gene and chromosomal positions. More
than 1200 breast tumors were collected from eight inde-
pendent breast studies and candidate metastasis suppres-
sor and promoting genes were found from a given set of
chromosomal regions [11]. Similarly, Hu et al. were able
to identify a new intrinsic gene-set for breast cancer sub-
type prediction by combining multiple microarray data-
sets to assess prognosis [12].
Several different meta-analysis approaches exist in the lit-
erature. In some, each individual study contributes rather
independently to the meta-analysis [13-15] whereas in
others the values are treated as members of a single study
thus requiring a generalized normalization step [16,17].
Direct comparison of gene expression values from multi-
ple studies may be relatively more problematic than com-
paring the effect size obtained from individual studies.
Yet, analysis of combined raw data is beneficial when
sample sizes of individual studies are small. Another
important concern in meta-analysis is the determination
of the minimum number of samples required to obtain
statistically reliable results [18]. One possible solution to
this problem is resampling; for example, one can use a
delete-d-jacknife procedure in which a subset of data is
excluded to find out the frequency of selecting a particular
gene as differentially expressed [18]. The number of repli-
cates required for producing stable differentially
expressed gene lists could also be determined based on a
related method known as leave-one-out resampling [19].
Existing meta-analytic approaches applied to different
types of cancer show the power of a combined study for
identifying novel genes not present in the existing litera-
ture (e.g., liver cancers) [20,21]. Invasive ductal carci-
noma (IDC) and invasive lobular carcinoma (ILC) make
up to 95% of all breast tumors (IDC: 50–80% and ILC:
10–15%) [2,22-24]. Although recent studies suggest dif-
ferences between the expression profiles of IDC and ILC,
the clinical progress, therapeutic response, and molecular
signature, there are also many similarities between IDC
and ILC tumors distinguishing them from normal breast
tissue [2,5,23,25]. However, meta-analysis of gene expres-
sion differences between normal breast tissue and such a
generalized set of breast tumors has not been reported to
date.
In the present study, we primarily aimed to develop a
novel methodology for the meta-analysis of independent
microarray datasets. Using this methodology, we provide
gene lists that (a) are discriminative of breast cancer types
(IDC, ILC) and normal breast cell populations, (b) may
yield breast tumor markers that are invariably expressed
across independent experiments, and (c) provide a set of
consistently differentially expressed gene candidates with
potential discriminative ability for tumor subtypes. Using
a method similar to delete-d-jacknife, a series of d sample
size values have been tested to assess the extent of varia-
bility across the tumor samples and the stability of differ-
ential expression. Comparison of probability value
distributions obtained for the test and randomized sam-
ples has led to determination of the degree of differential
expression between groups tested. Accordingly, we report
that the Sorlie et al. [1] and Zhao et al. [2] datasets were
highly comparable. Our resampling-based meta-analysis
led to the identification of genes not differentially
expressed when analyzed independently. Predictive abil-
ity of the meta-gene set was independently supported in
three other breast cancer microarray studies with informa-
tion on breast normal and tumor tissues [5,7,8] using
BRB-TOOLS [26]. A subset of the meta-gene-list was also
used as a classifier to accurately predict different molecu-
lar subtypes, such as luminal/basal and ER+/ER- based on
microarray datasets in which patient subtype classifica-
tion was available [7,8]. Moreover, selected candidates
from stable gene sets obtained from the meta-analysis
were validated by real-time qRT PCR. Use of resampling-
based meta-analysis combined with class prediction viaPage 2 of 16
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tumor-specific differentially expressed gene-set with pre-
dictive potential for tumor subtype classification.
Methods
Data retrieval for resampling-based meta-analysis
Two independent microarray gene expression data sets,
Sorlie et al. [1] and Zhao et al. [2], were downloaded from
the Stanford Microarray Database (SMD); http://genome-
www5.stanford.edu/[27]. Gene filtering options of SMD
were used for log transformation and median centering
the data arraywise. Expression values that were missing in
more than 20% of the data were excluded from the analy-
sis. Details of tumor specimen histology, available on
SMD, were used to restructure the experiments according
to breast tumor subtypes as invasive ductal carcinoma
(IDC), invasive lobular carcinoma (ILC) and normal sam-
ples. Datasets were combined with respect to probe IDs
using a set of customized perl routines (source codes are
available upon request). These two data sets combined
resulted in an initial list of 4769 IMAGE clones (3465
unique genes) common in both datasets (see Additional
file 1; Zhao dataset and Additional file 2; Sorlie dataset).
A total of 139 IDC (38 samples Zhao, 101 samples Sorlie
datasets), 29 (21 samples Zhao, 8 samples Sorlie datasets)
ILC and 7 (3 samples Zhao, 4 samples Sorlie datasets)
normal samples were available for further analysis.
Data Filtering
Data were filtered separately for ductal and lobular sam-
ples. IMAGE clones with more than 50% missing data in
either of the Sorlie or Zhao datasets were excluded from
the common clone set. Data filtering was further
improved by performing two-tailed Student's t-tests with
equal variance (Matlab®) between the Sorlie and Zhao
datasets for the IDC and ILC samples separately. Those
clones with probability values less than 0.05 (after Bonfer-
roni correction) were excluded from further analysis. This
two-step data filtering resulted in a common set of 1726
IMAGE clones for the analysis of ductal and normal sam-
ples, and 2029 IMAGE clones for the analysis of lobular
and normal samples. Upon taking the intersection of the
ductal-normal and lobular-normal clone sets, 1522
IMAGE clones were available for the ductal-lobular analy-
sis. The resulting clone subsets were further filtered by
removing IMAGE clones with more than 40% missing
data for the two groups in comparison (e.g., ductal and
normal) in the combined data before application of the
resampling steps. In addition, if an IMAGE clone had a
sample size (of normal samples) less than the resampling
sample size, data on this IMAGE clone was also removed.
Resampling and statistical analysis
We have used a resampling method for meta-analysis of
microarray data in which the significance of the differ-
ence between group medians (e.g. ductal vs. lobular)
could be tested upon a series of resampling schemes
from the original and multiple randomly shuffled data-
sets (Figure 1; code written in Matlab® using Statistics
Toolbox is available upon request). Accordingly, a preset
number of samples was selected from each group (i.e.,
IDC, ILC, normal) of the original dataset, referred herein
as the test. The p-value was calculated indicating the sig-
nificance of the difference between the group medians
based on the Wilcoxon Rank Sum Test. This test was
repeated for a series of i number of iterations; at the end
of each iteration scheme, a set of p-values (pt) per IMAGE
clone was obtained. The above procedure was also
applied to each of the shuffled datasets yielding pr1 and
pr2. P-value distributions were then tested in a pair-wise
fashion (i.e., pt vs. pr1; and pr1 vs. pr2) using the two-
sample Kolmogorov-Smirnov test for each clone in the
dataset (Figure 1). The resulting p-values were named as
kst and ksr, respectively. To obtain an estimate of the
false discovery rate (FDR), ksr values were sorted in the
ascending order and the kth value from the top (lowest p-
value) was determined as FDRobserved, where k equals the
expected value of FDR (e.g., 0.01) multiplied by the
number of IMAGE clones tested. FDRobserved was set as
the threshold according to which IMAGE clones were
assigned as significant or not. If kst of a particular gene
had a value that was smaller than the FDRobserved, the
gene was accepted to be significant.
Application to the breast cancer datasets
The above tasks were performed for a particular sample
size n (e.g., 3), repetitively for i number of times where
i = 10, 20, 30, ..., 100 and 150. For each particular i,
three parameters were recorded, namely, kst values, the
mean expression value of each of the two groups com-
pared, and the significance of the differential expres-
sion based on kst and ksr. These above steps were then
repeated with different sample sizes: For ductal vs. lob-
ular comparison, n was set to be 3, 4, 5, 6, 10, 15 and
20. On the other hand, since the total number of nor-
mal samples was 7, the highest sampling value could be
set to 6 for ductal vs. normal and lobular vs. normal
comparisons, and n equaled 3, 4, 5 and 6. These sample
size-iteration combinations led to 77 runs for ductal vs.
lobular analysis, and 44 runs for ductal vs. normal and
lobular vs. normal analyses. At the end, a final differen-
tially expressed gene set was determined for each of the
three comparisons (i.e., ductal vs. lobular, DL; ductal
vs. normal, DN; lobular vs. normal, LN) by gathering
the IMAGE clones that were assigned as significant in
90% or more of these 44 or 77 runs. The mean values
of each of the two groups in comparison obtained at n
= 20 (or 6, in the case of normal vs. tumor compari-
sons) and i = 150 were used as an estimate of the meas-
ure of expression.Page 3 of 16
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The ".cel files" of the three publicly available independent
microarray gene expression data sets, GDS2635 [5],
GDS2250 [7] and GDS1329 [4], were downloaded from
GEO [28] and processed by the BRB-ARRAYTOOLS [26].
All three datasets were obtained using the Affymetrix
HGU133A or HGU133 Plus 2.0 platform; thus they were
highly comparable. In GDS2635 the aim was to identify
gene expression profiles of microdissected ductal and lob-
ular carcinomas in relation to their normal ductal and
lobular cells (n = 10). The authors identified multiple
genes differentially expressed in comparisons between
ductal and lobular tumor and normal cells [5]. In the
GDS2250 study, a gene expression array-based analysis of
General meta-analysis schemeFigure 1
General meta-analysis scheme. Workflow is represented by boxes and arrows.
Median center data, arraywise
Exclude IMAGE clones with >40% missing data
Supervised re-sampling 
  Test     Shuffled 2 
Ranksum test: pt Ranksum test: pr1, pr2
Kolmogorov-Smirnov Test: kst, ksr
for each 
Shuffled 1 
Unsupervised re-sampling
Determine cut off value according to  FDRobserved
Select significant genes
Gene filtering with T-test
For each data set exclude IMAGE clones with >50% missing data
Restructure meta-data as ductal, lobular or normalPage 4 of 16
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cer (BLC), BRCA-associated breast cancer, and non-BLC,
was performed. They used 47 human breast tumor cases
to provide insight into the molecular pathogenesis of BLC
and BRCA1-associated breast cancer and the contribution
of X chromosome abnormalities to the pathogenesis of
BLC [7]. In GDS1329, Farmer et al. performed an analysis
of tumors from 49 breast cancer patients that were suc-
cessfully classified into luminal and basal classes, and a
novel molecular apocrine class. Apocrine tumors were
estrogen receptor negative ER(-) and androgen receptor
positive AR(+), while luminal tumors were ER(+) and
AR(+), and basal tumors were ER(-) and AR(-). Details of
the breast specimens (normal-tumor, non-basal like-
basal like, basal-luminal and ER (+)/ER (-)) available
from GEO database were used in the supervised class pre-
diction with a binary tree algorithm [26]. The common
genes between the re-analyzed microarray studies and the
meta-gene-lists were combined with respect to gene sym-
bols (perl source codes are available upon request).
Clinical Samples
Primary tumor samples and matched non-tumor breast
tissues were obtained from patients (n = 10) during sur-
gery and immediately snap-frozen in liquid nitrogen and
stored at -80°C until RNA extraction. The frozen tissue
samples were sectioned and mounted on glass slides. The
slides were stained with hematoxylin and eosin for his-
topathological examinations. Only those tumor samples
with more than 90% of tumor cells and matched tissue
pairs with normal histological examination were included
in this study. These frozen tissues were cut into 5-μm-
thick sections and used for RNA isolation and cDNA syn-
thesis. All the tumor samples had been classified as infil-
trating ductal carcinoma. The use of the tissue material in
this project was approved by the Research Ethics Commit-
tee of Ankara Numune Research and Teaching Hospital
and consents were obtained in accordance with the Hel-
sinki Declaration.
RNA extraction and cDNA synthesis
The frozen breast specimens were put into Trizol reagent
(AppliChem, Darmstadt, Germany), disrupted with a
homogenizer and total RNA was isolated according to the
manufacturer's instructions. Genomic DNA contamina-
tions were removed by on-column DNaseI treatment
(Macharel Nagel, Duren, Germany). The concentration of
the isolated RNA and the ratio of absorbance at 260 nm to
280 nm were measured with the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Montch-
anin, DE, USA) in triplicate.
First-strand cDNA was synthesized from 1 μg total RNA
using oligo(dT) primers using Revert Aid First strand
cDNA synthesis kit according to the manufacturer's
instructions (Fermentas, MD, USA). The cDNA was
diluted at a ratio of 1:5 before being used as a PCR tem-
plate and stored at -20°C until further use.
Real-Time quantitative RT-PCR
Real-time qRT-PCR analysis was performed using gene-
specific primer pairs (Additional file 3). Real-time qRT-
PCR was performed on the BioRad iCycler Instrument
(BioRad Laboratories, Hercules, CA, USA). The amplifica-
tion mixtures contained 1.0 μl of 1:5-diluted cDNA tem-
plate, 6.25 μl SYBR Green PCR Master Mix Buffer, and 10
pmol of forward and reverse primers in a total volume of
12.5 μl. Cycling conditions were as follows: an initial
incubation of 95°C for 5 min and then 45 cycles of 95°C
for 30 s and 60°C for 30 s during which the fluorescence
data were collected. To verify that the used primer pair
produced only a single product, a dissociation protocol
was added after thermocycling, determining dissociation
of the PCR products from 55°C to 95°C. Tumor and
matched normal samples were always analyzed in the
same run to exclude between-run variations and each
sample was studied in duplicate. A no-template control of
nuclease-free water was included in each run. An initial set
of randomly selected genes from the DN list was used for
real-time qRT-PCR validation studies. RAD21, GSN,
COX6C, MAF, SFRP1, SPTNB1, GSPT1, NME1, PTTG1 but
not MAF were also present in the LN list. Furthermore,
seven other genes with potential predictive power for
tumor subtype classification were studied by real-time
qRT-PCR. These genes included FN1, ID4, EGFR,
ADAMTS1, ATF3, IGFBP6, and PRNP. The geometrical
mean of ACTB, TBP and SDHA1 gene expression values
were used as internal control for relative gene expression
quantitation [29]. Primer sequences and accession num-
bers of these genes were given in Additional file 3. The
mean expression values obtained in resampling meta-
analysis runs were used as a measure for comparing with
the fold-change results obtained from the real-time qRT-
PCR validation studies; a Pearson correlation coefficient
was also calculated (Matlab®).
Results
Correlation of Sorlie and Zhao Datasets
Combining the datasets in meta-analysis requires that
they have similar expressions, both in magnitude and
individual variability. To assess whether the Sorlie and
Zhao datasets were correlated, a Pearson's correlation
coefficient was calculated between the mean expression
values of the ductal or lobular samples from each dataset,
respectively before and after performing t-tests (Figure 2).
Even before the removal of IMAGE clones showing signif-
icant differences between the studies, the mean expression
values of ductal samples from Sorlie were highly corre-
lated with those from Zhao; and a similar result was
observed for the lobular samples (r = 0.8329 and 0.8233,Page 5 of 16
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expressed IMAGE clones, the correlations between the
aforementioned datasets increased to 0.9389 and 0.8465
for the ductal and lobular samples, respectively. These
results ensured that there was significant correlation
between the Sorlie and Zhao datasets although they were
based on independent tumor and normal samples.
Distribution statistics for generation of meta-lists
In this report, we used global-median normalized and fil-
tered datasets since they minimized the number of
manipulations performed during gathering of the meta-
data (see Additional file 4). Accordingly, assessment of
significance was based on p-values obtained from the Kol-
mogorov-Smirnov analysis between test and random dis-
tributions (pt and pr1, respectively) of a gene in the meta-
data. For example, the GSN gene had a highly significant
differential expression between ductal and normal sam-
ples as evidenced by the highly skewed distribution
towards lower p-values whereas the RAP2A gene exhibited
a uniform distribution of p-values (Figures 3A, B and 3C,
D, respectively).
Effects of resampling on estimates of expression and 
differentially expressed gene number
We tested the effect of sample size and number of itera-
tions on the estimation of mean expression level and the
number of differentially expressed genes. For each run
performed with a different sample size, the change in
grand mean of expression (i.e., mean expression of all
IMAGE clones) as well as the number of differentially
expressed IMAGE clones were plotted with respect to the
increasing number of iterations (Figure 4). As the
number of iterations increased, the grand mean became
more stabilized. Expectedly, the magnitude of change in
mean values asymptotically decreased as the number of
iteration and sampling size increased (Figure 4A and
4C). On the other hand, the number of genes stated as
significant increased as a function of the number of iter-
ations and sampling size (Figure 4B, 4D). Significant
IMAGE clones made up more than 70% of all analyzed
genes at sampling size 6 with the highest iteration in
ductal vs. normal analysis whereas the same set-up
resulted in only 20% significant IMAGE clones in ductal
vs. lobular analysis.
Pearson correlation coefficients (r) between Sorlie and Zhao datasetsFigure 2
Pearson correlation coefficients (r) between Sorlie and Zhao datasets. Correlation plots between datasets after dif-
ferentially expressed IMAGE clones were filtered out based on t-tests. (A) Correlation between mean expression values of 
ductal samples (p < 0.05). (B) Correlation between mean expression values of lobular samples (p < 0.05).Page 6 of 16
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Examples for probability distributions of Wilcoxon rank sum testsFigure 3
Examples for probability distributions of Wilcoxon rank sum tests. Data were obtained where resampling size, n, 
equaled to 6 (100 iterations). Assessment of significance was based on p-values obtained from the Kolmogorov-Smirnov test 
between test and random distributions (pt and pr1, respectively). (A, C) For test data, GSN gene had a highly significant differ-
ential expression (significant at 100% of iterations, p = 0.00) between ductal and normal samples whereas RAP2A gene did not 
(significant at 5% of iterations, p = 0.98). (B, D) Probability values of both GSN and RAP2A, obtained from randomized data, 
were uniformly distributed. GSN; IMAGE: 214990 and RAP2A; IMAGE:36684.
BMC Cancer 2008, 8:396 http://www.biomedcentral.com/1471-2407/8/396
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Effect of change in sample size and number of iterations on mean expression values and number of significant IMAGE clonesFigure 4
Effect of change in sample size and number of iterations on mean expression values and number of significant 
IMAGE clones. For each of the runs performed with different sample sizes (n), the change in the mean expression value (A, 
C) and the number of IMAGE clones that were stated as differentially expressed (B, D) were plotted with respect to the 
increasing number of iterations. A and B refer to the results of ductal vs. normal analysis whereas C and D show the results of 
ductal vs. lobular analysis.
BMC Cancer 2008, 8:396 http://www.biomedcentral.com/1471-2407/8/396It is reasonable to assume that use of a single sample size
and iteration number may not be adequate to understand
the variability among the tumor samples (Figure 4). It
might instead be beneficial to consider all of the informa-
tion gathered from the individual runs. Accordingly, the
significant gene lists reported in this study were obtained
by taking only those IMAGE clones that were assigned as
significant in a given set of all resampling analyses per-
formed (90% or more for ductal-normal, DN; and lobu-
lar-normal, LN; and 80% or more for ductal-lobular, DL
comparisons) in an effort to minimize the effects of sam-
pling size and iteration number on p-values.
Characteristics of differentially expressed meta-gene lists
Differentially-expressed gene lists for DN and LN con-
tained 298 (282 genes) and 216 (202 genes) IMAGE
clones, respectively (see Additional files 5 and 6). On the
other hand, there were only 66 (65 genes) differentially
expressed IMAGE clones between the ductal and lobular
(DL) datasets for 80% criteria (see Additional file 7). The
size of these lists was dependent on the False Discovery
Rate (FDR) input value (herein set to 0.01) or the percent-
age of resampling runs considered for significance (i.e.,
90% or 80%). In order to obtain a larger number of genes
for DL analysis, the significance percentage value was set
to 80.
The same resampling procedures were also performed on
the individual datasets, Sorlie and Zhao, separately. Com-
pared to our meta-analysis these separate analyses
together could provide 91% of IMAGE clones that were
present in the significant DN list and LN list and 68% of
the IMAGE clones of the DL list. However neither of the
studies could supply 9% of the IMAGE clones of the DN
and LN list and 32% of the DL list (90% cut-off), each of
which corresponds to a novel contribution by our meta-
analysis (see Additional file 8 for meta-analysis specific
gene lists).
We also compared the final DL significant gene list with
the list of 52 genes reported by Zhao et al. [2]. The DL list
shared CDH1, AOC3, FADS2, SORBS1, ALDH1A1, LPL,
ANXA1 and AKR1C1 with that of Zhao et al. [2]. However,
our analysis did not assign reasonable significance to the
F11 and VWF genes according to the set cut-off criteria
(80%). The remaining genes in the Zhao gene list were not
encountered since they were not included in the com-
bined dataset used in the present meta-analysis. Meta-
analysis of these two datasets provided a total of 36 signif-
icant genes not previously reported by Zhao et al and
when either dataset is analyzed individually (see Addi-
tional file 7).
Validation of tumor vs. normal meta-gene lists by 
independent microarray datasets
Recent meta-analysis studies identified common cancer
signatures by combining microarray datasets from differ-
ent tissues for increasing accuracy of tumor vs. normal
class prediction [30,31]. In this study, we focused on
extracting a stable tumor molecular signature based on
two of the existing breast cancer studies that contain
microarray data on normal, IDC, and ILC tissue samples.
We also have validated the predictive power of the meta-
gene lists obtained through the resampling-based meta-
analysis using three additional breast cancer datasets,
which contain microarray data on 3 or more samples of
normal and tumor breast tissues (Table 1) [5,7,8]. Accord-
ingly, subsets of genes from DN and LN meta-gene lists
were able to predict the tumor vs. normal classes with
high accuracies, ranging from 80 to 100% (Table 1). Strik-
ingly, correlation between expression values obtained
from significant discriminators from each of the three
Table 1: Summary of GEO breast cancer microarray datasets and results of class prediction analysis for the meta-gene lists, DN 
(Ductal/Normal) and LN (Lobular/Normal).
Study GEO ID Class Meta gene-list
DN LN
N T Accuracy
(%)
Number of genes rDN Accuracy
(%)
Number of genes rLN
Turashvili [5] GDS2635 10 10 93 57 0.85 80 49 0.87
Richardson [7] GDS2250 7 40 100 145 0.86 100 96 0.78
Karnoub [8] GSE8977 15 7 95.5 109 0.72 95.5 89 0.81
Normal (N) and tumor (T) sample sizes, accuracy of prediction from binary tree algorithm (% accuracy), and the number of genes in classifier 
(number of genes) were shown for each study, separately. Correlation (rDN, rLN) of the classifier expression from each study with the DN and LN 
meta-gene expressions were also indicated (Pearson correlation, Minitab®; p < 0.001).Page 9 of 16
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was high (Table 1). This indicated that the DN and LN
lists harbored a robust expression profile for the breast
tumors when compared with normal breast tissue.
Prediction of tumor-subtypes
We extracted a small, highly correlated classifier gene sub-
set, which was commonly detected among the three
microarray studies and the meta-analysis, to identify a
more conservative gene set differentially expressed
between tumor and normal cells (Additional file 9).
Twenty-eight genes from the DN or LN meta-gene lists
intersected with the three other microarray datasets
(GDS2635, GDS2250, and GD1329); 17 of which were
differentially expressed between basal vs. non-basal and/
or ER status (Additional file 9). For example, ADAMTS1,
ATF3, IGFBP6, PRNP, EGFR, FN1, ID4, SPTBN1, and
SFRP1 genes from the DN list were found to significantly
different in expression between nonbasal-like vs. basal-
like tumors as well as basal and luminal subtypes of the
breast tumors (p < 0.05). All of the above genes except
FN1 were found to be significantly associated with the
tumor ER status (p < 0.05; Additional file 9).
Validation of ductal vs. lobular meta-gene list
Comparison of fold-change values of the DL meta-gene
list consisting of 65 genes with that of the Turashvili's DL
list (GDS2635) resulted in a high degree of correlation (r
= 0.53; p < 0.001), suggesting that the direction and mag-
nitude of expression change between the IDC and ILC
samples were largely consistent between data from differ-
ent microarray experiments. Furthermore, we combined
published expression data from IDC and ILC samples
from experiments performed by Bertucci et al [32] with
the meta-analysis results (Additional File 7). Some of the
members of the 65 meta-gene list were consistently down-
or up-regulated also in the Turashvili and Bertucci datasets
(i.e., down-regulated ALDH1A1 and RBP4 in IDC; and up-
regulated CDH1 and TFAP2A in IDC). Protein expression
levels of these four genes were investigated using the
Human Protein Atlas, a public resource for immunohisto-
chemistry (IH) of normal and pathological human tissues
http://www.proteinatlas.org/. IH data were available for
CDH1, TFAP2A, and RBP4 proteins; and only data from
antibodies exhibiting differential expression among
breast tumors were reported herein. Accordingly, 2 out of
3 ILC samples exhibited moderate to strong signals for
RBP4 (Antibody CAB00455) whereas 7 out of 9 IDC sam-
ples were either negative or had weak staining. CDH1 data
in the Protein Atlas database was not very informative
since the number of ILC samples were limited, but a mod-
erate signal was detected for the ILC sample whereas 5 out
of 6 IDC samples expressed CDH1 strongly (Antibody
CAB000087). Similarly, TFAP2A was weakly or moder-
ately expressed in the two ILC samples examined whereas
a moderate to strong staining was observed in 5 of the 9
IDC samples. Although sample size in the ILC samples in
the Human Protein Atlas database was limited, there was
a corresponding trend between the mRNA levels reported
by the present study and the protein level assessment
obtained from the Human Protein Atlas. Future studies
should include testing of the genes extracted by meta-
analysis using protein level studies such as Western blot-
ting or immunohistochemistry on a large set of IDC and
ILC samples to confirm their predictive power.
Validation of meta-analysis by real time qRT-PCR
We first selected nine genes that were found to be differ-
entially expressed in both the DN and LN lists (except
MAF) from the meta-gene list for validation of the meta-
analysis. Expression profiles of these genes were tested in
independent paired IDC breast tumor and non-tumor tis-
sue samples through real time qRT-PCR. Our results were
consistent with those of the meta-analysis such that GSN,
SPTBN1, SFRP1 and MAF were down-regulated in most
tumor samples with respect to their matched non-tumor
samples whereas COX6C, RAD21, GSPT1, NME1 and
PTTG1 were up-regulated (Figure 5). Additionally we
selected seven other genes, ATF3, ADAMTS1, EGFR,
PRNP, IGFBP6, ID4 and FN1, found to be differentially
expressed according to tumor subtype and ER+/ER- classi-
fication from the tumor-specific differentially expressed
gene-set. All except FN1 were found to be down-regulated
in tumor samples with respect to their normal counter-
parts. The meta-analysis results were supported by the
real-time qRT-PCR experiments since all tested genes
exhibited differences between matched normal and tumor
samples in the same direction as expected by the meta-
analysis (Pearson correlation coefficient, r = 0.78, p =
0.001).
Among the genes we used for validation through real time
qRT-PCR, ID4 was the gene found to be differentially
expressed between DN only by meta-analysis rather than
each study alone.
Discussion
Microarrays allow high-throughput analysis of expression
for thousands of genes and provide valuable information
for tumor studies. For example, individual microarray
studies have identified differentially expressed gene lists
for distinguishing breast cancer subtypes and normal
breast tissue [5,6,8,9]. Meta-analysis, on the other hand,
might increase the knowledge by gathering and process-
ing individual microarray datasets.
In the present study, we provided highly stable lists of dif-
ferentially expressed genes based on meta-analysis of two
breast cancer datasets [1,2]. We have used a resampling-
based strategy in which the effects of number of iterationsPage 10 of 16
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in which each IMAGE clone, at each run, was voted as
either significantly- or non-differentially expressed and
the significant counts then were added up. A percentage
value was obtained by dividing the number of significant
votes by the total number of votes and a threshold of 80–
90% for each IMAGE clone was chosen as a cut-off value
for this meta-analysis. The meta-analysis was able to
report multiple genes (i.e., 29, 21, and 6 genes for DN, LN,
and DL, respectively) which neither dataset could report
when analyzed individually.
Sample size greatly influences the reproducibility of the
significant gene lists, such that the lower the sample size
the less stable the gene lists become [19]. In addition, Qui
et al. [18] have shown that the stability of genes identified
as differentially expressed varies: some genes are consist-
ently stable whereas others are not, independent of the
statistical methodology used. Along these considerations,
our voting scheme provided an advantage for extracting
highly stable gene lists.
Different statistical methods are available for assessing
differential expression. Among these, non-parametric
tests allow for comparison of low sample size and distri-
bution-independent comparisons. Our choice of rank-
sum test was based on this idea; similarly, previous studies
reported the use of Kolmogorov-Smirnov test statistics to
compare the reference and sample distributions in the
context of Gene Ontologies [33]. We used a Kolmogorov-
Smirnov test statistic for comparison of test and random
distributions of p-values obtained from rank sum tests. In
generating random datasets, we applied a gene-wise per-
mutation algorithm that preserved the expression level
information. Based on gene-wise permutations, a set of
probability values that compare the actual and rand-
omized distributions allowed for the assessment of the
significance of the difference between groups tested using
the Kolmogorov-Smirnov tests.
Different studies can be normalized and directly com-
pared to each other in meta-analysis. Our comparisons
ensured that there was a significant correlation between
the Sorlie and Zhao datasets although these studies were
based on independent tumor and normal samples; and
the experimental procedures (e.g., amplification of RNA)
also varied considerably between the two studies. Median
rank scores [16] or quantile discretization algorithms have
frequently been used to transform gene expression values
from different studies to a common numerical range [17].
Validation of meta-analysis results by real-time qRT-PCRFigure 5
Validation of meta-analysis results by real-time qRT-PCR. Sixteen genes were selected from the ductal-normal (DN) 
significant meta-gene list for real-time qRT-PCR. Solid black bars refer to mean expression values (± SEM) of 10 independent 
IDC breast tumors normalized to their non-tumor pairs. White bars refer to the mean expression values from the combined 
meta-gene list.
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malized data correlated well (see Additional file 4), we
have used the former normalization method, with the
least number of data manipulation steps, before combin-
ing these two datasets.
Due to the large number of comparisons involved in
microarray data analysis, it is important to take into
account the false positive error rate and control it for the
number of tests performed. FDR is a well-known method-
ology for multiple-test correction; its estimation relies on
calculation of the number of false positives in a randomly
permuted set of experiments [34]. Therefore, we made
comparisons between randomly shuffled datasets to
obtain an estimate of FDR; and kept the value of FDR low
(% 0.01) to reduce the number of false positives.
Invasive breast tumors comprise 18 different histological
types [24], most of which are classified as invasive ductal
carcinoma not otherwise specified (IDC NOS). ILC, on
the other hand, makes about 10–15% of all breast tumors
and it is histologically characterized by uniform tumor
cells arranged in single-files or concentrically localized
around ducts [35]. ILC exhibit heterogeneity just like IDC;
and a high-grade aggressive form of ILC known as pleo-
morphic lobular carcinoma (PLC) exists [36]. Bertucci et
al. [32] reported that IDC and ILC were histologically and
genomically distinguishable from each other among the
ER(+) grade II invasive breast tumors. Furthermore, ILC
molecular subtypes were reported to include the typical
and IDC-like ILCs, yet the CDH1 mutation and/or under-
expression was common but not universal to ILCs in gen-
eral [35]. Low-grade breast tumors were generally
characterized by ER(+), PR(+) and with limited genomic
aberrations whereas high grade tumors were generally
ER(-) and PR(-) and had complex karyotypic changes.
However, molecular differences among subtypes may not
surpass the differences between any tumor cell and the
normal since the degree of genomic stability in normal
cells would be relatively higher.
The other three studies presenting data on ILC and IDC,
Turashvili et al. [5], Sorlie et al. [1] and Zhao et al. [2] have
used a more diverse selection of tumor samples. Although
IDC and ILC have distinctive clinical and pathological
characteristics and differ in their ER status and metastatic
behaviors [22], meta-analysis of Zhao and Sorlie datasets
indicated that a small number of genes distinguished
between the expression profiles of IDC and ILC patients.
On the other hand, the number of genes that were differ-
entially expressed between normal and IDC or normal
and ILC samples was much greater. Indeed, Turashvili et
al. [5] has also reported only 28 genes that were signifi-
cantly differentially expressed between IDC and ILC sam-
ples, which were extracted using laser-dissection, a more
recent methodology allowing for precise collection of a
given cell population. These findings suggest that the
degree of molecular differences between IDC and ILC are
indeed smaller than those between the tumor and normal
classes.
Comparisons between the meta-analysis and the Turash-
vili and Bertucci studies pointed out to CHD1, TFAP2A,
RBP4, and ALDH1A1 genes as commonly modulated.
Indeed, CDH1 is one of the best-studied discriminators
for ductal/lobular breast cancer specimens in the literature
by immunohistochemistry and at the genomic level. In
breast cancer, reduced CDH1 expression has been found
in 50% of invasive ductal carcinomas, whereas CDH1
expression was almost always absent in infiltrating lobu-
lar carcinoma (ILC) [1,2,5,32,37,38]. TFAP2A was shown
to be highly expressed in ductal tumor cells while normal
cells expressed TFAP2A in the inner glandular cell layer
[39]. On the other hand, nuclear TFAP2 expression was
shown to be higher in lobular than ductal breast carcino-
mas [40]. There is no report on RBP4 in the literature in
connection with ductal vs. lobular breast cancer distinc-
tion while ALDH1A1 protein levels were shown to exhibit
differences among the ductal carcinoma patients [41]. The
candidates identified in the meta-analysis then are likely
to be discriminatory at the mRNA level rather than the
protein level since protein localization and variability in
intensity might make the ductal vs. lobular tissue discrim-
ination less clear. Therefore, it is of paramount impor-
tance that future confirmatory studies include use of
independent ILC and IDC samples for quantitative
expression profiling of the selected candidate genes.
On the other hand, analyses of Sorlie, Zhao, and Turash-
vili data showed that tumor cells were remarkably distinct
from their respective normals in their transcription pro-
files implicating that whatever the subtype structure
underneath, most of the variability among samples was
due to changes during tumorigenesis. Accordingly, the
idea that genes discriminating tumor from normal in a
stable manner also may have information on the state of
the tumorigenesis is a valid one.
Breast tumor subtype classification remains a complicated
issue due to difficulties associated with the presence of
multiple interacting factors such as the presence or
absence of node-filtration, ER-positivity, metastatic
potential, different degrees of genomic instability, and
tumor cell origin. For example, basal like cancers have dis-
tinct molecular expression profiles and histological differ-
ences when compared with the luminal type [42]. Nielsen
et al. [43] have categorized basal like breast cancer tumors
as having variable levels of expression of one of the three
stem/basal markers, namely CK5/6, EGFR, and c-kit.
Luminal cell markers, on the other hand, include CK8,Page 12 of 16
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lobular epithelial cells [44]. However, both the basal and
luminar histochemical markers may exist simultaneously
suggesting that breast cancer is rather a heterogeneous tis-
sue [45]. It is also evident that tumors with a triple nega-
tive status (ER-, PR-, HER2-) are more likely to belong to
the basal type [43,46]. In general, gene expression studies
associated the basal-like breast tumors with high prolifer-
ative abilities and thus having a worse prognosis when
compared with the luminal subtype of breast cancers
[1,47]. Thus identification of genes best classifying breast
cancer into intrinsic molecular subtypes like luminal,
HER2+/ER- and basal-like also allows determination of
risk factors and likely prognosis for the patients. The
importance of identification of these different subtypes is
that they differ in clinical outcome and molecular subtype
signatures thus help predict clinical outcome and
response to therapy.
Differentially expressed genes between tumor and normal
states (DN and LN) also keep information about intrinsic
subtypes. Accordingly, meta-analysis identified ATF3,
ADAMTS1, EGFR, PRNP, IGFBP6, ID4, SFRP1, SPTBN1,
and FN1 with ability to classify tumors into basal and
luminal subclasses. Additionally most of them accurately
differentiated ER(+) and ER(-) tumors (Additional file 9).
Among those genes, ID4 was found to be a novel tumor
suppressor gene in normal human breast tissues and epi-
genetically silenced in breast cancer cell lines and primary
breast tumors [48,49]. As supporting information for our
data, de Candia et al. suggested that the expression of ID4
in the mammary duct epithelium may be regulated by
estrogen depending on the differential expression pattern
of ID4 in ER(+) and ER(-) breast tumors [50]. SFRP1 on
the other hand is a frizzled-related protein that plays a
role in a variety of cellular processes, including control of
cell polarity, cell fate determination, and malignant trans-
formation. In previous studies, loss of SFRP1 was found to
be associated with cancer progression and poor prognosis
in breast cancer [51,52]. EGFR is known to be a positive
immunohistochemical marker for basal-like breast can-
cers and it was shown to accurately identify basal-like
tumors from microarray data with potential therapeutic
implications [53,54]. Activating transcription factor 3
(ATF3) is a member of the ATF/cyclic AMP response ele-
ment-binding family of transcription factors. It was
shown to enhance apoptosis in the untransformed mam-
mary epithelial cells while protecting the aggressive cells
and enhancing cell motility. Array analyses indicated that
ATF3 upregulated the expression of several genes in the
tumor necrosis factor pathway in the untransformed
mammary epithelial cells. However, the expression of sev-
eral genes implicated in tumor metastasis including
fibronectin (FN1) was upregulated in aggressive cells.
ATF3 was also shown to regulate the transcription of FN1,
one of the genes obtained in the present study. ATF3 gene
copy number was at least doubled in 80% of the breast
tumors examined; protein levels also were elevated in
close to 50% of these tumors [55].
Since the normal vs. tumor classification was strikingly
distinct based on meta-analysis, and a gene-set with the
capacity for breast cancer subtype classification, we fur-
ther analyzed a set of normal matched tumors for selected
genes from the meta-gene list using real-time qRT-PCR.
The selected 16 significant genes were shown to have
expression profiles similar to those found from the meta-
analysis. Our findings also suggested that these genes
could be used as predictors of tumor status regardless of
the origin of the reference samples, i.e., a matched or
pooled reference tissue. Since the number of samples used
in qRT-PCR was relatively small, increasing the sample
size may help generalize our results to a wider range of
breast tumor samples.
There was a high level of correlation between fold changes
obtained from the DL meta-genes and those from the
Turashvili dataset, regardless of the different sample
extraction methods used in each study (i.e., frozen sec-
tions and laser-dissection, respectively). The meta-gene
list discriminating between ductal and lobular breast
tumor samples at the mRNA level requires further confir-
mation at the protein level to better assess discriminatory
power. Future validation studies might concentrate on
whether meta-analysis specific genes also participate in
prediction of level of prognosis and/or time to disease-
free survival.
Conclusion
In this study, meta-analysis of two independent compara-
ble microarray data sets allowed us to provide genes that
are able to discriminate IDC and ILC and normal mam-
mary cells from the tumors that either study by itself was
not able to identify. We also provided highly generalized
and stable gene lists that could be used for prediction of
tumor or normal status. The meta-gene list for tumor/nor-
mal comparison had a striking predictive ability based on
comparisons made with three independent microarray
datasets. The resampling approach proposed herein has the
ability to detect a set of differentially expressed genes, with
the least amount of within-group variability. This meta-
analytic approach thus provides a method to combine two
or more independent cancer data sets leading to the identi-
fication of differentially expressed gene sets for better
understanding of cancer development and progression.Page 13 of 16
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